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Abstract: This reports the preliminary outcome of a transpalpebral electrical retinal stimulation therapy for age-related 
macular degeneration (ARMD). 
Twenty-one patients consisting of 16 with wet-type (Group-W) and 5 with dry-type (Group-D) ARMD with a mean age 
of 73.9 ± 9.5 years (range 51 to 85 years) were recruited for this study. Transpalpebral electrical retinal stimulation (20 
minutes, 800 μA) was applied on the patients 4 times per day for up to 1 month. The mean best-corrected visual acuity 
(Early Treatment Diabetic Retinopathy Study [ETDRS] score) changed from 29.5±5.1 to 31.8±5.0 in Group-W and from 
39.8±4.7 to 42.9±4.9 in Group-D. Neither ocular nor systemic adverse effects were observed with the exception of one pa-
tient who developed contact dermatitis. Due to several limitations such as lack of control, patients’ learning effect, etc, the 
efficacy of the therapy could not be drawn. This preliminary study, however, showed that the transpalpebral electrical 
retinal stimulation therapy can be non-invasively applied on wet-type ARMD patients. 
INTRODUCTION 
  Age-related macular degeneration (ARMD) is a leading 
cause of blindness in industrialized countries, which affects 
primarily the choriocapillaris, Bruch’s membrane, and the 
retinal pigment epithelium [1]. 
  The exudative form, so-called wet type, is characterized 
by the development of choroidal neovascularization (CNV). 
Recently, photodynamic therapy or vitreous surgery is being 
successfully performed to restore vision but only in selected 
cases where photoreceptor degeneration is still fresh [2-7]. 
Recently, positive results of anti-vascular endothelial growth 
factor (VEGF) have accumulated [8,9], but the effect is lim-
ited in advanced stages. Furthermore, no effective treatment 
exists for eyes with geographic atrophy, drusen, and pigment 
alterations, so-called dry type. A growing volume of investi-
gations have reported the keys to reveal the etiology, includ-
ing the Age-related Eye Disease Study (AREDS), which 
provided a novel first step towards preventive medicine for 
the disease [10-14]. However, advanced damage cannot be 
restored. A polymorphism (Tyr402His) in the complement 
factor H (CFH) gene has recently been reported to increase 
the risk of AMD [15-17]. 
  Recent reports have noted that electrical stimulation has 
neuroprotective potential by means of the enhancement of  
neurotrophic factors in several different neural tissues by 
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subretinal implants [18,19]. Although the exact mechanism 
has yet to be elucidated, several investigators have shown the 
upregulation of neurotrophins in the central and peripheral 
nervous system in relation to electrical stimulation [20-22]. 
Thus, applying electrical stimulation to the retina may in-
duce a protective effect on the diseased retina through the 
activation of the endogenous neuroprotective agents. It is, 
however, difficult to stimulate the retina electrically in a rou-
tine clinical environment. The subretinal implants were re-
ported to upregulate neurotrophic factors, resulting in a pro-
tective effect on the remaining retinal circuitry [23,24]. The 
drawback to this novel treatment is that surgery is required. 
Morimoto et al. [20] reported a less invasive way based on 
the finding that novel transcorneal electrical stimulation res-
cues retinal ganglion cells by activating endogenous retinal 
IGF-1 system, which has long been known to evoke light 
sensations or cortical potentials that stem from inner retinal 
neurons [25-28]. 
  These findings prompted us to examine the feasibility of 
utilizing transpalpebral electrical retinal stimulation therapy 
on patients with wet-type ARMD. 
PATIENTS AND METHODS 
  Twenty-seven eyes with wet-type ARMD (Group W) and 
7 eyes with dry-type ARMD (Group D) were studied. The 
patients consisted of 15 males and 1 female, aged 51 to 85 
years with a mean of 73.3 ± 9.8 years (± SD) in Group W 
and 5 males, aged 63 to 85 years with a mean of 75.7 ± 9.2 
years (± SD) in Group D. The procedures used conformed to 
the tenets of the Declaration of Helsinki, and written in-
formed consent was obtained from each individual who par-Transcutaneous Electrical Retinal Stimulation Therapy  The Open Ophthalmology Journal, 2008, Volume 2    133 
ticipated in this study after explanation of the procedures. 
This prospective interventional case study was approved by 
the Institutional Review Board of Keio University Hospital. 
Eyes with a wet-type or dry-type ARMD lesion were re-
cruited for this study. The lesion had to involve the geomet-
ric center of the foveal avascular zone. 
  Patients were excluded if they had any significant ocular 
disease other than subfoveal CNV or geographic atrophy, 
which affected visual acuity, a history of intraocular or laser 
surgery within 6 months, or if they had taken any medication 
used for AMD such as vitamins or lutein in the 6 months 
prior to the examination. Patients whose condition met the 
criteria of photodynamic therapy (PDT) or antiVEGF ther-
apy of intravitreal pegaptanib injection, which was ongoing 
as a clinical trial, were also excluded. Consequently consecu-
tive patients were enrolled. Eyes with pathologic myopia, 
which was defined as an eye that requires a distance correc-
tion of at least -6.0 diopters or eyes with an axial length of 
more than 26.5 mm, were also excluded. 
  A microcurrent of 800 μA was transpalpebrally applied to 
both eyes by using a microcurrent stimulator (Fig. 1, Skylark 
Device & Systems Co., Ltd., Taiwan). One session lasted for 
20 minutes and was performed 4 times per day. The 20-minute 
protocol consisted of a monophasic pulse with a frequency of 
290 Hz for 1 minute, 31 Hz for 2 minutes, 8.9 Hz for 10 min-
utes, and 0.28 Hz for 7 minutes. The transcorneal electrical 
stimulation was clinically applied using 300 to 2000 μA of 20 
Hz stimulation for 30 minutes with an interval of one month to 
the patients with optic neuropathy [29]. The details of the pro-
tocol for electrical retinal stimulation have not yet been estab-
lished, and the protocol in the transpalpebral electrical stimu-
lation is to be determined. 
  Best-corrected visual acuity testing, the Early Treatment 
Diabetic Retinopathy Study (ETDRS) score, slit-lamp exami-
nation, funduscopy, fluorescein angiography, and automated 
static visual field testing, were performed before and 4 weeks 
after the application of the daily microcurrent treatment. A 
masked examiner performed the visual acuity examinations. 
The results of Humphrey central 30-2 perimetry (Carl Zeiss 
Meditec, Dublin, CA) with more than 4 poor fixation (about 
20% or more), more than 3 false positive data (33.3% or more), 
or more than 3 false negative data (33.3% or more) were ex-
cluded from the analysis. The mean deviation measured by 
Humphrey central 30-2 perimetry (Carl Zeiss Meditec, Dublin, 
CA), which assesses the sensitivity distribution in the central 
retinal area, was used for statistical evaluation. 
  The patients were asked 4 weeks after the treatment to 
rate the subjective therapeutic effect as poor, fair, good, and 
very good. For analysis the result was converted to scores of 
1, 2, 3, and 4 as poor, fair, good, and very good, respectively. 
  For the statistical procedure, visual acuity of 'counting 
fingers' and 'hand motion' were assigned to 20/20000 and 
20/200000, respectively, according to the previous report 
[30]. The paired t-test was performed to determine the 
changes of visual acuity and the mean deviation of the auto-
mated static perimetry. 
RESULTS 
  All the patients reported phosphene when the microcur-
rent was provided. This can be interpreted that the retina was 
electrically stimulated. Best-corrected visual acuity before 
and 4 weeks after treatment is shown in the Table 1. 
 
Fig. (1). Top: Appearance of the transcutaneous electrical retinal 
stimulation therapy. Top: The skin electrodes are applied to patches 
on both eyelids and the microcurrent runs through them. The patient 
remains seated during the 20-minute treatment. Bottom: The 
schema of the transcutaneous electrical retinal stimulation therapy. 
The [L] indicates eyelid. The [E] indicates cutaneous contact elec-
trode. *: The dotted lines show the electrical current which is regu-
lated in a symmetric bidirectional way. 
Table 1.  Snellen Visual Acuity 
 
  Wet-Type  
ARMD
1 (n
2=27) 
Dry-Type  
ARMD (n=7) 
Pre-treatment  C.F.
3 – 20/25 
20/400 
20/1000– 20/50 
20/160 
Post-treatment  20/100 – 20/32 
20/400 
20/100 – 20/40 
20/200 
Data are shown as range (median). 
1ARMD = age-related macular degeneration. 
2n=number of eyes, 
3C.F = counting fingers. 
 
  Although the improvement of visual acuity did not reach 
statistical significance in the entire group, the average of the 
ETDRS scores significantly improved from 29.5±5.1 to 
31.8±5.0 (mean±SE, P=0.0407, paired t-test, Fig. (2 top), 
Table  2) in Group-W and from 39.8±4.7 to 42.9±4.9 in 134    The Open Ophthalmology Journal, 2008, Volume 2  Shinoda et al. 
Group-D (P=0.0401, paired t-test, Fig. (2 top), Table 2). The 
averaged mean deviation of the automated perimetry in 
Group-W was -13.3±3.1 dB before treatment and -12.4±3.1 
dB after treatment (mean±SE, P=0.0247, paired t-test, Fig. 
(2 bottom), Table 2). However, in Group-D, no significant 
improvement was shown; from -9.3±3.2 dB to -9.3±2.8 dB 
(P>0.05, paired t-test, Fig. (2 bottom), Table 2). 
 
Fig. (2). Changes in visual function after the microcurrent therapy 
at 4 weeks. Top: The averaged Early Treatment Diabetic Retinopa-
thy Study (ETDRS) visual acuity score significantly improved from 
29.5±5.1 to 31.8±5.0 (mean±SE, P=0.0407) in wet-type age-related 
macular degeneration (ARMD) patients and in dry-type ARMD 
patients (from 39.8±4.7 to 42.9±4.9, P=0.0401). Bottom: The aver-
aged mean deviation of the automated perimetry improved from -
13.3±3.1 dB to -12.4±3.1 dB after treatment (mean±SE, P=0.0247) 
in wet-type ARMD patients while in dry-type ARMD patients, it 
changed from -9.3±3.2 dB to -9.3±2.8 dB (P>0.05). The ‘N.S.’ 
indicates ‘not significant’. 
  The subjective score in each group is shown in Fig. (3). 
Generally patients were satisfied and preferred to continue 
the treatment. However, it showed no significant correlation 
with the other parameters, such as visual acuity and the aver-
aged mean deviation. No obvious change was observed ei-
ther by slit-lamp or funduscopy. No ocular and systemic 
complications were observed except one patient who devel-
oped contact dermatitis on both superior lids. We decided to 
stop treatment, considering the adverse side effect to be seri-
ous, despite the 62-year-old man’s strong preference to con-
tinue the treatment and instead initiated treatment using 
ofloxacin ointment. 
CONCLUSIONS 
  A number of trials have been performed to develop an 
effective way to control the progression and complications of 
ARMD, but it remains limited [2-7]. This is attributed to the 
lack of understanding of the pathogenesis and final irreversi-
ble damage of the neural network including photoreceptor 
cells. Recently, subretinal implants were reported to have a  
 
Table 2.  ETDRS Score and Mean Deviation 
 
ETDRS Score  Mean  
Deviation 
Case  Gender Age Laterality  Type 
Pre  
Tx 
Post  
Tx 
Pre  
Tx 
Post  
Tx 
1 M  83  L  W  36  46  -6.30  -7.36 
2 M  71 
R 
L 
W 
W 
79 
18 
77 
21 
-6.71 
-11.22 
-1.44 
-7.18 
3 M  75 
R 
L 
W 
W 
33 
5 
37 
8 
-17.93 
-21.48 
-14.86 
-18.09 
4 M  81 
R 
L 
W 
W 
1 
50 
2 
52 
-18.69 
-1.98 
-21.54 
-3.22 
5 M  71  L  W  19  22  -10.54  -9.63 
6 M  62 
R 
L 
W 
W 
62 
57 
64 
65 
-4.34 
-8.50 
-2.77 
-8.32 
7 M  51  R  W  43  54  -4.61  -5.29 
8 M  68 
R 
L 
W 
W 
72 
26 
67 
21 
-4.37 
-3.42 
-2.64 
-6.23 
9  M  85 R  W  0 4  -28.94  -27.76 
10 M 57 
R 
L 
W 
W 
70 
41 
65 
39 
-4.89 
-4.00 
-4.32 
-4.63 
11 M 72 
R 
L 
W 
W 
3 
0 
8 
4 
-29.56 
-30.03 
-27.27 
-28.33 
12 M 84  L  W  19 18  -11.13  -8.07 
13 F  79 
R 
L 
W 
W 
15 
0 
18 
1 
-29.34 
-28.96 
-28.09 
-29.02 
14 M 77 
R 
L 
W 
W 
17 
1 
23 
20 
-10.29 
-12.75 
-9.22 
-14.04 
15 M 79 
R 
L 
W 
W 
3 
9 
2 
6 
-25.22 
-15.18 
-26.03 
-13.45 
16 M 78 
R 
L 
W 
W 
45 
72 
48 
66 
-4.45 
-3.50 
-3.61 
-1.55 
1 M  71  R  D  26  31  -2.84  -3.57 
2 M  84  R  D  68  71  -3.71  -9.46 
3 M  85  L  D  39  42  -13.02  -9.63 
4 M  76 
R 
L 
D 
D 
7 
35 
5 
35 
-25.57 
-18.96 
-23.46 
-14.26 
5 M  63 
R 
L 
D 
D 
36 
68 
42 
74 
-1.47 
0.58 
-2.43 
-2.36 
M: male; F: female; R: right: L: left; W: wet type; D: dry type; mean deviation is 
shown as value (dB); ETDRS: Early Treatment Diabetic Retinopathy Study. 
 
protective effect on the remaining retinal neurons, possibly 
by means of upregulating neurotrophic factors [19,23,24]. 
Consequently, the electrical stimulation of the retinal circuit 
might have a potential neuroprotective effect on the degener-
ating retina. Survival of photoreceptors following transcor-
neal electrical stimulation was reported in Royal College of 
Surgeons’ rats [31]. Therefore, we performed a pilot study to  
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investigate a therapeutic effect of electrical retinal stimula-
tion on the degenerating retina. A novel treatment, transcor-
neal electrical stimulation, invented by Morimoto et al. [20] 
showed dramatic advancement compared with subretinal 
implantation of an electrical device. However, that procedure 
is invasive, especially on the cornea, and requires clinical 
treatment. The current study shows a less invasive way that 
can be performed by the patient himself even at home. 
  In the 1960s, a number of investigators reported clinical 
application of electrical retinal stimulation for evaluating 
retinal function, but not for treatment [25-28]. In such inves-
tigations, normally the electrical stimulation was provided 
using a corneal contact lens and no severe adverse effects 
were reported. As expected, in the current study, serious ad-
verse effects, such as severe vision loss or corneal erosion, 
were not seen. One case among a total of 23 cases (4.3%) 
developed contact dermatitis, which should be considered an 
inherent complication of the therapy. In this case, it was not 
severe, treatment was stopped and the application of oflox-
acin ointment led to immediate disappearance of the dermati-
tis. Such complications might be avoided by using a different 
material for attaching the skin electrodes. Since this is an 
almost completely new treatment, it would be necessary for 
clinicians to be reminded that there might be some other un-
known potential hazard. 
  Our results demonstrated that the microcurrent retinal 
stimulation has the potential of improving retinal function of 
the wet-type ARMD, although these are preliminary results 
and the study’s weaknesses limit the generalization of the 
findings: small number of patients studied, relatively short 
follow-up times, and absence of a control group. Therefore, 
the findings from this study cannot be interpreted as justify-
ing the definite efficacy of the microcurrent therapy for 
ARMD. The information and data obtained from this study 
are, however, useful in that they bring to light the future pos-
sibility of novel alternative treatment for a refractory age-
related eye disease. In the present study, the wet-ARMD 
seemed to benefit, whereas the dry-AMD did not in terms of 
visual field parameter. It is speculated that the photoreceptor 
cell and/or RPE cell, which benefits this therapy, should be 
freshly or mildly damaged, and that relative acute damage in 
wet-type ARMD could be recovered. Further investigation of 
larger numbers and a longer observation period designed as a 
randomized control trial and also basic research will be nec-
essary to determine the feasibility of the therapy, and to un-
derstand the therapeutic role of the microcurrent on the pro-
gressively degenerating photoreceptors. 
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